about
Virologic and immunologic evidence supporting an association between HHV-6 and Hashimoto's thyroiditisSelecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancersFamilial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases.Congenital cytomegalovirus infection: patterns of fetal brain damageEpimutational profile of hematologic malignancies as attractive target for new epigenetic therapiesA lymphomagenic role for HIV beyond immune suppression?Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatmentImmune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disordersIdentification and characterization of an Epstein-Barr virus-specific T-cell response in the pathologic tissue of a patient with Hodgkin's diseaseMultiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4.Phenotypic features and genetic characterization of male breast cancer families: identification of two recurrent BRCA2 mutations in north-east of Italy.Proteins specifically hyperexpressed in a coeliac disease patient with aberrant T cells.Chlamydia infection and lymphomas: association beyond ocular adnexal lymphomas highlighted by multiple detection methods.B cell clonality in gastric lymphoid tissues of patients with Sjögren's syndrome.Simian immunodeficiency virus and human immunodeficiency virus type 1 matrix proteins specify different capabilities to modulate B cell growth.Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation CarriersLatent membrane protein 1 deletion mutants accumulate in reed-sternberg cells of human immunodeficiency virus-related Hodgkin's lymphoma.Elevated serum transforming growth factor beta1 levels in Epstein-Barr virus-associated diseases and their correlation with virus-specific immunoglobulin A (IgA) and IgM.The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disordersPathogenetic and histogenetic features of HIV-associated Hodgkin's disease.Epstein-Barr virus infection and chronic lymphocytic leukemia: a possible progression factor?Multiparametric analyses of human PBMCs loaded ex vivo with a candidate idiotype vaccine for HCV-related lymphoproliferative disorders.Infectious agents in mucosa-associated lymphoid tissue-type lymphomas: pathogenic role and therapeutic perspectives.What's new in the biology and treatment of undifferentiated carcinoma of nasopharyngeal type?Glucocorticoids promote the proliferation and antagonize the retinoic acid-mediated growth suppression of Epstein-Barr virus-immortalized B lymphocytes.Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: new immunobiological and molecular insights on a long-standing etiopathogenic association.Differential down-modulation of HLA class I and II molecule expression on human tumor cell lines upon in vivo transfer.Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriersPrevalence of Borrelia burgdorferi infection in a series of 98 primary cutaneous lymphomas.Pathogenesis of human reactive-appearing "non-monomorphous" malignant lymphoproliferative disorders: a hypothesis.An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriersHigh serum levels of soluble CD40-L in patients with undifferentiated nasopharyngeal carcinoma: pathogenic and clinical relevance.Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disordersMicrosatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosisAlpha 4 beta 7 integrin expression is associated with the leukemic evolution of human and murine T-cell lymphoblastic lymphomas.Serum antibody response to lytic and latent Epstein-Barr virus antigens in undifferentiated nasopharyngeal carcinoma patients from an area of nonendemicityHigh prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability.Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.
P50
Q21131390-CACE383C-46A6-49F9-9669-AE07FC871C3BQ21260381-8F75E4A4-BB66-4CB2-8126-7B3F8310A968Q21260436-D4EB2849-E470-4A37-B9E5-846F08D4E722Q24276226-B5F507EC-9845-4F21-8C5D-5D5543EDC0B3Q26744080-36D6B673-F2C1-4950-A4A4-7C63CA8C22E0Q26771672-CE92C084-0319-4959-84CC-703AECFEC175Q26798038-A9DD8977-C5CC-4BEA-AD48-5BD8DABD3C7DQ27491280-039E769D-832B-4558-A240-CB20304A4015Q28294744-5D5FC920-3B2D-4C41-963E-34F5F2FE14B8Q30452157-E66C2BB6-B1D8-4C81-93C6-193C25E97B68Q33246295-0C48873A-BAAC-4DB5-B75C-AC159ADC1D53Q33276657-7C80E7DA-5B5C-462E-AFF9-CFB40FCC5D09Q33369691-5CC01957-1FE4-421E-83E8-3E7FBFA66D00Q33578921-8A9AF369-E4BB-4BF2-B782-6FB3D204FF0CQ33602706-73ABEC6C-2748-4665-827A-9F46135A5510Q33614244-6E1F2A09-47CF-485B-9770-DE885FFB68D8Q33780975-E6162804-D83E-4758-A651-B84E3FD067B5Q33799292-C16A8E6B-DCC8-4F7E-A9FC-66F45901F606Q34166602-994FB7F7-A570-42FE-B5C1-62E491F7C231Q34292013-112FB08D-4943-4AFA-AF42-096A71E5D7CEQ34387817-F104A971-B31B-4DE3-8FBD-8E02A3CF6AFCQ34427560-8D45EC30-EDD3-4EC2-9D05-E9C7FFEADDFFQ34498266-29AA5411-D96D-43E5-9CDA-DC85A9253F53Q34507651-F3D11002-FF6F-4D2A-98F9-D69F459527CAQ34509553-468F7909-8A6A-4266-A41B-B42F09EF421AQ34996054-F4D65F47-EB94-464A-8347-A3E7B1C88E54Q35086680-F6A76E63-8C03-4C65-B15C-EBA30245E495Q35402927-1FD94ACC-F71B-4F15-8086-28FDC9B66B73Q35523236-09B74198-1714-4082-ADD6-C2A709B29CFDQ35599807-03F37C15-A8BF-4D05-ACA0-F56DE6E3D2E9Q35602069-E1278F6E-AC5B-495D-A0B9-1BC52AF39003Q35618307-940E26D4-5E36-4BC1-907C-81A458FE89BAQ35674802-F06DF1AE-3569-4215-995A-36C62F973AB3Q35737888-688F1649-28AE-4DEE-87C2-46C29B2101E9Q35738744-3E28F4CF-109F-475C-8051-3024DF20D9E8Q35746560-F4AEA508-77D7-46D1-A7B3-AA88342DA27FQ35764367-76C0FC87-5B34-41F5-AE3E-F8C43C64C412Q35783467-AE1D6E4D-0E6F-414B-94F1-4138F708B9BCQ35787046-E0C3FFB5-D1F5-43D3-A01C-7B1DC071DB96Q35789363-5E6994CF-DD39-4C84-8CA7-3D9FCC51891B
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Riccardo Dolcetti
@ast
Riccardo Dolcetti
@en
Riccardo Dolcetti
@es
Riccardo Dolcetti
@nl
Riccardo Dolcetti
@sl
type
label
Riccardo Dolcetti
@ast
Riccardo Dolcetti
@en
Riccardo Dolcetti
@es
Riccardo Dolcetti
@nl
Riccardo Dolcetti
@sl
altLabel
Dolcetti R
@en
prefLabel
Riccardo Dolcetti
@ast
Riccardo Dolcetti
@en
Riccardo Dolcetti
@es
Riccardo Dolcetti
@nl
Riccardo Dolcetti
@sl
P1053
O-3832-2015
P106
P21
P2798
P31
P3829
P496
0000-0003-1625-9853